Copyright Reports & Markets. All rights reserved.

Global Anti-epileptic Drugs for Pediatrics Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Anti-epileptic Drugs for Pediatrics

      • 1.1 Definition of Anti-epileptic Drugs for Pediatrics
      • 1.2 Anti-epileptic Drugs for Pediatrics Segment by Type
        • 1.2.1 Global Anti-epileptic Drugs for Pediatrics Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 1st generation
        • 1.2.3 2nd generation
        • 1.2.4 3rd generation
      • 1.3 Anti-epileptic Drugs for Pediatrics Segment by Applications
        • 1.3.1 Global Anti-epileptic Drugs for Pediatrics Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospitals
        • 1.3.3 Retail pharmacies
        • 1.3.4 Online pharmacies
      • 1.4 Global Anti-epileptic Drugs for Pediatrics Overall Market
        • 1.4.1 Global Anti-epileptic Drugs for Pediatrics Revenue (2014-2025)
        • 1.4.2 Global Anti-epileptic Drugs for Pediatrics Production (2014-2025)
        • 1.4.3 North America Anti-epileptic Drugs for Pediatrics Status and Prospect (2014-2025)
        • 1.4.4 Europe Anti-epileptic Drugs for Pediatrics Status and Prospect (2014-2025)
        • 1.4.5 China Anti-epileptic Drugs for Pediatrics Status and Prospect (2014-2025)
        • 1.4.6 Japan Anti-epileptic Drugs for Pediatrics Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Anti-epileptic Drugs for Pediatrics Status and Prospect (2014-2025)
        • 1.4.8 India Anti-epileptic Drugs for Pediatrics Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Anti-epileptic Drugs for Pediatrics
      • 2.3 Manufacturing Process Analysis of Anti-epileptic Drugs for Pediatrics
      • 2.4 Industry Chain Structure of Anti-epileptic Drugs for Pediatrics

      3 Development and Manufacturing Plants Analysis of Anti-epileptic Drugs for Pediatrics

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Anti-epileptic Drugs for Pediatrics Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Anti-epileptic Drugs for Pediatrics
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Anti-epileptic Drugs for Pediatrics Production and Capacity Analysis
      • 4.2 Anti-epileptic Drugs for Pediatrics Revenue Analysis
      • 4.3 Anti-epileptic Drugs for Pediatrics Price Analysis
      • 4.4 Market Concentration Degree

      5 Anti-epileptic Drugs for Pediatrics Regional Market Analysis

      • 5.1 Anti-epileptic Drugs for Pediatrics Production by Regions
        • 5.1.1 Global Anti-epileptic Drugs for Pediatrics Production by Regions
        • 5.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Regions
      • 5.2 Anti-epileptic Drugs for Pediatrics Consumption by Regions
      • 5.3 North America Anti-epileptic Drugs for Pediatrics Market Analysis
        • 5.3.1 North America Anti-epileptic Drugs for Pediatrics Production
        • 5.3.2 North America Anti-epileptic Drugs for Pediatrics Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Anti-epileptic Drugs for Pediatrics Import and Export
      • 5.4 Europe Anti-epileptic Drugs for Pediatrics Market Analysis
        • 5.4.1 Europe Anti-epileptic Drugs for Pediatrics Production
        • 5.4.2 Europe Anti-epileptic Drugs for Pediatrics Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Anti-epileptic Drugs for Pediatrics Import and Export
      • 5.5 China Anti-epileptic Drugs for Pediatrics Market Analysis
        • 5.5.1 China Anti-epileptic Drugs for Pediatrics Production
        • 5.5.2 China Anti-epileptic Drugs for Pediatrics Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Anti-epileptic Drugs for Pediatrics Import and Export
      • 5.6 Japan Anti-epileptic Drugs for Pediatrics Market Analysis
        • 5.6.1 Japan Anti-epileptic Drugs for Pediatrics Production
        • 5.6.2 Japan Anti-epileptic Drugs for Pediatrics Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Anti-epileptic Drugs for Pediatrics Import and Export
      • 5.7 Southeast Asia Anti-epileptic Drugs for Pediatrics Market Analysis
        • 5.7.1 Southeast Asia Anti-epileptic Drugs for Pediatrics Production
        • 5.7.2 Southeast Asia Anti-epileptic Drugs for Pediatrics Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Anti-epileptic Drugs for Pediatrics Import and Export
      • 5.8 India Anti-epileptic Drugs for Pediatrics Market Analysis
        • 5.8.1 India Anti-epileptic Drugs for Pediatrics Production
        • 5.8.2 India Anti-epileptic Drugs for Pediatrics Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Anti-epileptic Drugs for Pediatrics Import and Export

      6 Anti-epileptic Drugs for Pediatrics Segment Market Analysis (by Type)

      • 6.1 Global Anti-epileptic Drugs for Pediatrics Production by Type
      • 6.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type
      • 6.3 Anti-epileptic Drugs for Pediatrics Price by Type

      7 Anti-epileptic Drugs for Pediatrics Segment Market Analysis (by Application)

      • 7.1 Global Anti-epileptic Drugs for Pediatrics Consumption by Application
      • 7.2 Global Anti-epileptic Drugs for Pediatrics Consumption Market Share by Application (2014-2019)

      8 Anti-epileptic Drugs for Pediatrics Major Manufacturers Analysis

      • 8.1 Mylan N.V
        • 8.1.1 Mylan N.V Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.1.2 Mylan N.V Product Introduction, Application and Specification
        • 8.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Cephalon, Inc
        • 8.2.1 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.2.2 Cephalon, Inc Product Introduction, Application and Specification
        • 8.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 GlaxoSmithKline plc
        • 8.3.1 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.3.2 GlaxoSmithKline plc Product Introduction, Application and Specification
        • 8.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Janssen Pharmaceuticals
        • 8.4.1 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.4.2 Janssen Pharmaceuticals Product Introduction, Application and Specification
        • 8.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Novartis AG
        • 8.5.1 Novartis AG Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.5.2 Novartis AG Product Introduction, Application and Specification
        • 8.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Pfizer, Inc
        • 8.6.1 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.6.2 Pfizer, Inc Product Introduction, Application and Specification
        • 8.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Sanofi S.A
        • 8.7.1 Sanofi S.A Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.7.2 Sanofi S.A Product Introduction, Application and Specification
        • 8.7.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 UCB Pharma Limited
        • 8.8.1 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.8.2 UCB Pharma Limited Product Introduction, Application and Specification
        • 8.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Sunovion Pharmaceuticals Limited
        • 8.9.1 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.9.2 Sunovion Pharmaceuticals Limited Product Introduction, Application and Specification
        • 8.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Valeant Pharmaceuticals International, Inc
        • 8.10.1 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Production Sites and Area Served
        • 8.10.2 Valeant Pharmaceuticals International, Inc Product Introduction, Application and Specification
        • 8.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Zogenix
      • 8.12 GW Pharmaceuticals
      • 8.13 Insys
      • 8.14 Zynerba

      9 Development Trend of Analysis of Anti-epileptic Drugs for Pediatrics Market

      • 9.1 Global Anti-epileptic Drugs for Pediatrics Market Trend Analysis
        • 9.1.1 Global Anti-epileptic Drugs for Pediatrics Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Anti-epileptic Drugs for Pediatrics Regional Market Trend
        • 9.2.1 North America Anti-epileptic Drugs for Pediatrics Forecast 2019-2025
        • 9.2.2 Europe Anti-epileptic Drugs for Pediatrics Forecast 2019-2025
        • 9.2.3 China Anti-epileptic Drugs for Pediatrics Forecast 2019-2025
        • 9.2.4 Japan Anti-epileptic Drugs for Pediatrics Forecast 2019-2025
        • 9.2.5 Southeast Asia Anti-epileptic Drugs for Pediatrics Forecast 2019-2025
        • 9.2.6 India Anti-epileptic Drugs for Pediatrics Forecast 2019-2025
      • 9.3 Anti-epileptic Drugs for Pediatrics Market Trend (Product Type)
      • 9.4 Anti-epileptic Drugs for Pediatrics Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Anti-epileptic Drugs for Pediatrics Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.

        The global Anti-epileptic Drugs for Pediatrics market was valued at 830 million US$ in 2018 and will reach 1530 million US$ by the end of 2025, growing at a CAGR of 7.9% during 2019-2025.
        This report focuses on Anti-epileptic Drugs for Pediatrics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-epileptic Drugs for Pediatrics market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Anti-epileptic Drugs for Pediatrics in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Anti-epileptic Drugs for Pediatrics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Mylan N.V
        Cephalon, Inc
        GlaxoSmithKline plc
        Janssen Pharmaceuticals
        Novartis AG
        Pfizer, Inc
        Sanofi S.A
        UCB Pharma Limited
        Sunovion Pharmaceuticals Limited
        Valeant Pharmaceuticals International, Inc
        Zogenix
        GW Pharmaceuticals
        Insys
        Zynerba

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        1st generation
        2nd generation
        3rd generation

        Segment by Application
        Hospitals
        Retail pharmacies
        Online pharmacies

        Buy now